Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase 1b: To determine the safe and tolerable Phase 2 dose of LY2157299 in combination with radiochemotherapy with temozolomide (TMZ) in patients with glioma. Phase 2a: To confirm the tolerability and evaluate the pharmacodynamic effect of LY2157299 in combination with standard radiochemotherapy treatment in patients with newly diagnosed GBM (as measured by changes in response biomarkers and their relationship to clinical benefit [for example, 12-month overall survival rate]).
Critère d'inclusion
- Glioblastoma Multiforme (GBM)